文献速递白血病

急性髓系白血病首次复发患者的修订预后模型

A revised prognostic model for patients with acute myeloid leukemia and first relapse.
PubMed 文献 · Blood Adv · 2025-01-01

研究基于HOVON-SAKK队列943例强化诱导后复发AML患者,用随机生存森林筛选9个与1年OS相关的变量并赋分,建立三组预后模型,在NCRI-AML18 trial的377例复发患者中验证,三组1年OS在开发与验证队列中均区分明显。

要点

  • 模型纳入复发间隔、年龄、白细胞计数、TP53突变、FLT3内部串联重复、核心结合因子异常、t(v;11q23)/KMT2A重排及复杂/单体核型共9个变量。
  • 开发队列三组1年OS:有利51%±3%、中间29%±3%、不良14%±2%。
  • 验证队列三组1年OS:有利51%±4%、中间26%±5%、不良14%±3%。

核心结论

  • 修订的AML复发模型优于既往首次复发后结局的预后模型,其分层可能支持定制二线治疗。

研究设计与样本

  • 开发队列为HOVON-SAKK研究中943例接受强化诱导治疗后复发的AML患者,采用随机生存森林算法评估诊断时临床参数、细胞遗传学异常和分子变量与总生存的关联。
  • 验证队列为NCRI-AML18 trial入组的377例复发患者。

主要发现

  • 开发队列复发时中位年龄58岁,按2022欧洲白血病网分类有利风险22%、中间风险31%、不良风险48%,三分之一患者在首次完全缓解期接受异基因移植。
  • 变量选择得到9个与1年OS相关的变量:复发间隔、年龄、白细胞计数、突变TP53、FLT3内部串联重复、核心结合因子异常、t(v;11q23)/KMT2A重排、复杂/单体核型,按估计风险比赋分。
  • 开发队列三组1年OS分别为有利51%±3%、中间29%±3%、不良14%±2%。
  • 验证队列三组1年OS分别为有利51%±4%、中间26%±5%、不良14%±3%。
  • 验证确认该模型提高了预测首次复发AML患者结局的准确性。

关键数值与推荐

  • 9个变量按估计风险比赋分,定义三个预后组。
  • 开发队列1年OS:有利51%±3%、中间29%±3%、不良14%±2%。
  • 验证队列1年OS:有利51%±4%、中间26%±5%、不良14%±3%。

临床怎么用

  • 原文结论指出该分层可能支持定制二线治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Most patients with acute myeloid leukemia (AML) may obtain remission upon induction chemotherapy, but relapse is frequent and associated with poor survival. Previous prognostic models for outcomes after relapse lacked analysis of comprehensive molecular data. A validated prognostic model integrating clinical, cytogenetic, and molecular variables may support treatment decisions. We studied 943 patients with AML who relapsed after intensive induction treatment in a development cohort (HOVON-SAKK). A random survival forest algorithm was used to evaluate the association of clinical parameters, cytogenetic abnormalities, and molecular variables at diagnosis with overall survival (OS). Relapsing patients (n = 377) who were enrolled in the NCRI-AML18 trial were used for validation. In the development cohort, the median age at relapse was 58 years, and patients were classified as 2022 European LeukemiaNet favorable (22%), intermediate (31%), and adverse risk (48%). One-third underwent allogeneic transplantation in the first complete remission. Variable selection yielded 9 variables associated with 1-year OS, including relapse-free interval, age, white blood cell count, mutated TP53, FLT3 internal tandem duplication, core-binding factor abnormalities, t(v;11q23)/KMT2A rearrangement, and complex/monosomal karyotype, which were assigned points according to their estimated hazard ratios. Three prognostic groups were defined with distinct 1-year OS in both development (favorable, 51% ± 3%; intermediate, 29% ± 3%; and poor, 14% ± 2%, respectively) and validation cohorts (51% ± 4%, 26% ± 5%, and 14% ± 3%, respectively). Validation confirmed the improved accuracy in predicting outcomes for patients with AML in first relapse. The revised AML relapse model improved on previous prognostic models for outcomes after first relapse. It provides stratification that might support tailoring second line treatment.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. van der Maas NG, Breems D, Klerk CPW, et al. A revised prognostic model for patients with acute myeloid leukemia and first relapse. Blood Adv. 2025. PMID: 40402082. doi:10.1182/bloodadvances.2025015797

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。